Investment Firm Compensation: Why AUM Alone Isn’t Enough
We just wrapped an investment firm consulting project where we looked at the firm’s compensation by both total AUM and size of most recent fund. We found the data to be interesting, so we’re sharing some of the analysis with you in this month’s digest. One of the most influential ways to customize investment firm compensation is […]
The State of Compensation for US Private Biotech Companies
According to PitchBook, “Biopharma companies’ willingness to go public appears to be making a tentative reversal after a long drought…The real drive behind this resurgence, according to investors, is the M&A market.” We looked at our YoY biotech compensation data and used a preview of data from our upcoming US Private Biotech Compensation Report to see […]